Situations Leading to Reduced Effectiveness of Current Hand Hygiene against Infectious Mucus from Influenza Virus-Infected Patients

Ryohei Hirose,a,b Takaaki Nakaya,b Yuji Naito,a Tomo Daidoji,b Risa Bandou,b,c Ken Inoue,a Osamu Dohi,a Naohisa Yoshida,a Hideyuki Konishi,a Yoshito Itoha

aDepartment of Molecular Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan
bDepartment of Infectious Diseases, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan
cDepartment of Forensics Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan

ABSTRACT Both antiseptic hand rubbing (AHR) using ethanol-based disinfectants (EBDs) and antiseptic hand washing (AHW) are important means of infection control to prevent seasonal influenza A virus (IAV) outbreaks. However, previous reports suggest a reduced efficacy of ethanol disinfection against pathogens in mucus. We aimed to elucidate the situations and mechanisms underlying the reduced efficacy of EBDs against IAV in infectious mucus. We evaluated IAV inactivation and ethanol concentration change using IAV-infected patients’ mucus (sputum). Additionally, AHR and AHW effectiveness against infectious mucus adhering to the hands and fingers was evaluated in 10 volunteers. Our clinical study showed that EBD effectiveness against IAV in mucus was extremely reduced compared to IAV in saline. IAV in mucus remained active despite 120 s of AHR; however, IAV in saline was completely inactivated within 30 s. Due to the low rate of diffusion/convection because of the physical properties of mucus as a hydrogel, the time required for the ethanol concentration to reach an IAV inactivation level and thus for EBDs to completely inactivate IAV was approximately eight times longer in mucus than in saline. On the other hand, AHR inactivated IAV in mucus within 30 s when the mucus dried completely because the hydrogel characteristics were lost. Additionally, AHW rapidly inactivated IAV. Until infectious mucus has completely dried, infectious IAV can remain on the hands and fingers, even after appropriate AHR using EBD, thereby increasing the risk of IAV transmission. We clarified the ineffectiveness of EBD use against IAV in infectious mucus.

IMPORTANCE Antiseptic hand rubbing (AHR) and antiseptic hand washing (AHW) are important to prevent the spread of influenza A virus (IAV). This study elucidated the situations/mechanisms underlying the reduced efficacy of AHR against infectious mucus derived from IAV-infected individuals and indicated the weaknesses of the current hand hygiene regimens. Due to the low rate of diffusion/convection because of the physical properties of mucus as a hydrogel, the efficacy of AHR using ethanol-based disinfectant against mucus is greatly reduced until infectious mucus adhering to the hands/fingers has completely dried. If there is insufficient time before treating the next patient (i.e., if the infectious mucus is not completely dry), medical staff should be aware that effectiveness of AHR is reduced. Since AHW is effective against both dry and nondry infectious mucus, AHW should be adopted to compensate for these weaknesses of AHR.

KEYWORDS hand hygiene, antiseptic hand rubbing, antiseptic hand washing, ethanol-based disinfectant, viscosity, mucus, sputum, influenza A virus, diffusion, fluid simulation, disinfectants, influenza
Prevention of influenza A virus (IAV) transmission during annual outbreaks of seasonal influenza is a major issue (1–3). Although droplet infection is most frequent, contact infection is also an important infection route (1, 4–6). Hand hygiene is a commonly used method for prevention of contact infection and is recommended by the Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) (7–10). There are two recognized techniques for performing hand hygiene: antiseptic hand rubbing (AHR) with alcohol-based disinfectants, such as 80% (wt/wt) ethanol-based disinfectants (EBDs), and antiseptic hand washing (AHW) (11).

EBDs are promoted based on the premise that they inactivate IAV in infectious mucus. While the effect of EBDs on pathogens in mucus such as sputum is reportedly satisfactory in actual use (12, 13), studies show that organic matter such as mucosal proteins may decrease this effectiveness (14–16). Since organic matter contained in hand dirt or body fluids may reduce EBD effectiveness, methods and standards for evaluating disinfectant efficacy by adding organic matter as a load material have been established by the American Society for Testing and Materials (ASTM) and the European Committee for Standardization (CEN) (17–20). EBDs comply with these standards and are used in medical institutions around the world.

We previously reported that EBD effectiveness against IAV in mucus may be reduced due to physical factors (e.g., viscoelasticity) and not chemical factors (e.g., organic matter) (21, 22). Disinfectant effectiveness against bacteria in biofilms decreases due to the physical factors of biofilms (23–25). Because mass transfer is limited in biofilms (26, 27), a disinfectant solution takes a long time to reach the center of a biofilm. Therefore, bacteria in biofilms are protected from disinfectants and survive longer (26, 28–30). Human mucus, including sputum, is a viscoelastic substance that shares physical properties with biofilms (31). Therefore, mucus may also protect IAV from disinfectants due to its physical properties.

Disinfectant effectiveness against IAV in mucus has not been evaluated based on the physical properties of mucus, and the mechanisms mediating IAV survival in mucus are yet unknown. Elucidation of these mechanisms will help clarify the limitations of current AHR regimens in disinfecting infectious mucus. Assessment of disinfectants in the presence of mucus may help the development of effective disinfectants. With identification of conditions leading to attenuation of the effectiveness of disinfectants, more effective AHR methods can be proposed.

In this study, we aimed to demonstrate the limited effectiveness of EBD against IAV in mucus (spum). We further sought to elucidate the mechanisms responsible for this limitation and the situations where this limitation occurs.

RESULTS

Physical properties and complete drying time of mucus. We performed a rheological analysis of the fluid flow properties of saline and the mucus samples (see Table S1 in the supplemental material). All mucus samples showed characteristics of a pseudoplastic fluid (a fluid whose viscosity decreases as the shear-rate increases). The viscosity of the mucus was significantly higher than that of saline (P < 0.001) at all shear rates (0.01 to 100 s⁻¹ [Fig. 1A]).

We also measured other physical properties (Fig. 1B; see Fig. S1 in the supplemental material). The mean contact angle (the angle between the liquid and contact surfaces) of the mucus samples was higher than that of saline (54.9 ± 2.7 versus 21.8 ± 0.8°; P < 0.001). Additionally, the mean surface tension of the mucus samples was lower than that of saline (46.9 ± 2.0 versus 71.4 ± 0.6 mN/m; P < 0.001), and the density of the mucus samples was lower than that of saline in the normal temperature range of 20 to 37°C.

Furthermore, the time required for 5 μl of saline or mucus samples to completely dry and solidify on a glass plate was measured. The mean complete drying time of the mucus samples was longer than that of saline (33.1 ± 2.7 versus 18.7 ± 0.8 min; P < 0.001 [Fig. 1C]).
Ethanol diffusion in mucus. Coefficients were determined for ethanol concentrations of 10 to 80%, and a fitting curve was prepared from the values (see Fig. S2 in the supplemental material). In the presence of 80% ethanol, the mean diffusion coefficient in mucus was $1.8 \times 10^{-10} \text{m}^2/\text{s}$, and the coefficient in saline was $3.6 \times 10^{-10} \text{m}^2/\text{s}$ (Fig. 1C).

In a simulation of changes in ethanol concentration that was conducted in Open-source Field Operation And Manipulation (OpenFOAM) software, considering only diffusion phenomena (and using the diffusion coefficients shown in Fig. S2), the ethanol concentration increase rate (ECIR) was indeed lower in mucus than in saline (see Fig. S3 in the supplemental material).

Measurement of the changes in ethanol concentrations in mucus. With a saline sample, the ethanol concentration increased to $>40\%$ within 30 s, whereas the ethanol concentration in the mucus samples reached 40% by $\sim 180$ s, demonstrating that the ECIR in mucus was lower than that in saline (Fig. 2A). However, in completely dried saline and dried mucus samples, the ethanol concentration increased to $>40\%$ in approximately 10 s, and the ECIRs were comparable between the two sample types (Fig. 2A). Furthermore, our data show that IAV used in this study was completely inactivated after exposure to $31\%$ ethanol for 30 s (Fig. 2B). Therefore, the minimum ethanol concentration that can completely inactivate IAV was set to 31% in this study.

The mean times required for the ethanol concentration to reach 31% were 19.9 s for saline, 159.0 s for mucus, 6.9 s for dried saline, and 7.9 s for dried mucus (Fig. 2C). The time required for the ethanol concentration to reach 31% was approximately 8 times longer in mucus than in saline. Moreover, viscosity (100 s$^{-1}$) correlated positively with the time required for the ethanol concentration to reach 31%, with a correlation coefficient of 0.908 ($P = 0.001$) (Fig. 2D).

Initial fluid simulation of the changes in ethanol concentrations in mucus. The differences in contact angle, viscosity, and diffusion coefficient should each result in a
lower ECIR for mucus than for saline (Fig. 3A). Fluid simulation was conducted using all of the measured physical property values and diffusion coefficients to demonstrate that the physical properties of mucus greatly affect the ECIR in mucus (Fig. 4).

In the saline mixture, the ethanol concentration in all regions increased to 31% in 19.1 s. In contrast, in the mucus mixture with sample no. 1, 10, and 19, the ethanol concentration in all regions increased to 31% in 142.1, 116.2, and 94.7 s, respectively. The time required for the ethanol concentration to reach 31% was approximately 5 to 8 times longer in mucus than in saline, which was relatively consistent with the results of ECIR analysis by ethanol concentration measurement (Fig. 2C and Fig. 4B).

**In vitro inactivation tests for evaluation of EBD efficacy.** In a control experiment, IAV in 5 μl saline was completely inactivated within 30 s of exposure to 95 μl EBD containing 80% (wt/wt) ethanol. In contrast, IAV in all 19 mucus samples survived exposure to EBD for more than 180 s (Fig. 5A). The IAV survival ratio (survival following incubation with EBD relative to survival following incubation with phosphate-buffered saline [PBS]) was significantly higher in mucus than in saline at all exposure times (P < 0.005 for all comparisons [Fig. 5B]). The time required for EBD to completely inactivate IAV (the complete inactivation time) in mucus was approximately eight times longer than it was in saline (258.5 ± 31.4 versus 30 s [Fig. 5C]). Moreover, the complete inactivation time correlated positively with the time required for the ethanol concentration to reach 31%, with a correlation coefficient of 0.927 (P = 0.001) (Fig. 5D). Interestingly, both IAV in dried saline and IAV in dried mucus were inactivated rapidly.
within 15 s (Fig. 5B and C). These results were in agreement with the results of ECIR analysis by ethanol concentration measurement in saline and mucus (Fig. 2C and Fig. 3).

**Clinical research on the efficacy evaluation of AHR or AHW.** The clinical analysis showed that although IAV in saline was completely inactivated by AHR using EBD within 30 s, IAV in all mucus samples remained active, even after AHR for 120 s, and was completely inactivated by AHR within 240 s. The log reduction of IAV in mucus was significantly lower than that in saline after AHR for 30, 60, and 120 s (i.e., the IAV survival ratio in mucus was significantly higher than that in saline). The efficacy of AHR was also examined after allowing the saline and mucus samples to dry completely after placing them on the fingers. IAV was inactivated rapidly by AHR within 30 s in both dried mucus samples and dried saline. Furthermore, IAV was inactivated rapidly by AHW within 30 s under all conditions (in both undried and dried mucus samples and undried and dried saline [Table 1]).

**Additional fluid simulation of the changes in ethanol concentrations in mucus.** Finally, we tried to simulate the reaction conditions of the ethanol concentration measurement and the inactivation tests more faithfully.

In the simulated mixing of saline and EBD, the ethanol concentration in all regions increased to ≥31% within 30 s (Fig. 6A; see Movie S1 in the supplemental material). Simulations for mucus mixtures were performed with mucus viscosity reduced to 16.7 or 12.5% of the measured value (see Materials and Methods for an explanation of the reason). In this simulation, the central region of the mucus remained at <31% ethanol for >30 s indicating a low ECIR, which corresponded with the experimental results (Fig. 6B; see Movie S2 in the supplemental material). All low-ethanol regions disappeared by ~60 s. Running of the simulation with a mucus viscosity at 16.7 or 12.5% of the measured value demonstrated that the ECIR was lower at the higher viscosity (see Fig. S4A in the supplemental material), suggesting that viscosity was a determining factor.
FIG 4 Initial fluid simulation of the changes in ethanol concentrations in mucus. (A) The initial simulation reproducing the mixing of 20 µL of saline/mucus and 380 µL of EBD in a well of a 96-well plate was conducted. Figure S6 shows the physical characteristic (Continued on next page)
factor for ECIR in mucus and that this affects the level of mixing between EBD and mucus by convection.

As a supplemental study to evaluate the validity of this fluid simulation, low-viscosity mucus (12.5 and 16.7% of the measured value) with physical properties almost similar to those applied to this simulation was prepared by dilution of a mucus sample with water, and the time course of the change in ethanol concentration following addition of the EBD was measured. The ethanol concentration at low mucus viscosities of 12.5 and 16.7% increased to 31% in 45.9 and 51.8 s, respectively (Fig. S4B), which was generally compatible with the results of this fluid simulation (Fig. S4A and C). Moreover, the result of the initial fluid simulation, which was conducted under the same low-viscosity conditions as this additional simulation, was generally compatible with the results of this fluid simulation (Fig. S4A and D).

DISCUSSION

It is widely known that the effects of disinfectants such as EBDs are attenuated by organic matter contained in body fluids: thus, evaluation of EBD effectiveness...
The effectiveness of disinfectants, have not been identified (such as sputum, major factors other than organic matter, which may reduce the effectiveness of disinfectants on pathogens in infectious mucus such as IAV). Building further on our previous research (12–14), we elucidated the situations and mechanisms in which the effectiveness of EBD against IAV in infectious mucus is extremely weakened, and we clarified the weak points of current AHR regimens and contact infection prevention strategies.

Based on the fluid simulations using measured physical properties and diffusion coefficients, the ECIR in mucus was expected to be much slower than the ECIR in saline (Fig. 3A). In fact, measurement of the ethanol concentration in saline and mucus revealed that the time required for the ethanol concentration to reach 31% (i.e., the minimum concentration at which IAV is completely inactivated) throughout the mucus was considerably low; this was because of decreased diffusion and convection phenomena due to the unique physical properties (particularly the high viscosity) of infectious mucus, which caused prolongation of the time required for EBD to exert its disinfecting effects on IAV in infectious mucus.

In this clinical study, infectious mucus prepared from sputum samples collected from IAV-infected patients was applied to human fingers, and in situ inactivation tests were performed. We aimed to reproduce the situation in which infectious mucus discharged from IAV-infected patients adheres to the fingers of medical staff. There was close agreement between inactivation test results obtained from in situ and in vitro settings. The effectiveness of AHR regimens using EBDs on IAV in mucus was extremely

| Sample  | Disinfection time (s) | IAV log reduction by conditiona |  |  |  |
|---------|-----------------------|--------------------------------|---|---|---|
|         |                       | Nondrying                       | Drying |  |  |
|         |                       | AHR | P | AHW | AHR | AHW |
| Saline  | 30                    | >5  |   | >5  | >5  | >5  |
|         | 60                    | >5  |   | >5  | >5  | >5  |
|         | 120                   | >5  |   | >5  | >5  | >5  |
|         | 240                   | >5  |   | >5  | >5  | >5  |
| Mucus   | All samples           | 30  | 0.84 ± 0.28 | 0.002 | >5  | >5  | >5  |
|         | 60                    | 1.87 ± 0.33 | 0.002 | >5  | >5  | >5  |
|         | 120                   | 2.95 ± 0.36 | 0.002 | >5  | >5  | >5  |
|         | 240                   | >5  |   | >5  | >5  | >5  |
| Each sample | No. 1   | 30  | 0.70 ± 0.49 | 0.002 | >5  | >5  | >5  |
|         | 60                    | 1.55 ± 0.55 | 0.002 | >5  | >5  | >5  |
|         | 120                   | 3.00 ± 1.14 | 0.008 | >5  | >5  | >5  |
|         | 240                   | >5  |   | >5  | >5  | >5  |
|         | No. 10                | 30  | 0.66 ± 0.30 | 0.002 | >5  | >5  | >5  |
|         | 60                    | 1.86 ± 0.82 | 0.002 | >5  | >5  | >5  |
|         | 120                   | 2.57 ± 0.62 | 0.002 | >5  | >5  | >5  |
|         | 240                   | >5  |   | >5  | >5  | >5  |
|         | No. 19                | 30  | 1.17 ± 0.38 | 0.002 | >5  | >5  | >5  |
|         | 60                    | 2.21 ± 0.67 | 0.002 | >5  | >5  | >5  |
|         | 120                   | 3.29 ± 0.75 | 0.004 | >5  | >5  | >5  |
|         | 240                   | >5  |   | >5  | >5  | >5  |

aIAV, influenza A virus; AHR, antiseptic hand rubbing; AHW, antiseptic hand washing. Statistics are presented as mean ± SD with the Wilcoxon signed-rank test. The log reduction values between saline and mucus conditions were compared.
reduced compared to that in saline, and infectious mucus containing IAV that adhered to the fingers was not effectively inactivated at 30 s. Current hand hygiene methods recommended by the CDC and WHO involve the use of disinfectants such as EBDs for 15 to 30 s (7–10). However, our results suggest that this disinfection time is insufficient for the disinfection of infectious mucus of IAV-infected patients adhered to the fingers/hands and that current contact infection prevention and AHR regimens using EBDs are not sufficient to prevent IAV outbreaks. On the other hand, AHW completely inactivated IAV in infectious mucus within 30 s, indicating that the AHW regimen is more suitable than AHR regimen for inactivation of infectious mucus, including IAV.

The liquids (culture medium, buffer solution, and saline) that are typically used as media to transfer pathogens when evaluating the effectiveness of disinfection methods have physical properties similar to those of pure water (a Newtonian fluid with extremely low viscosity). These liquids do not accurately simulate the physical properties of infectious body fluids, which include non-Newtonian fluids with relatively high viscosity, such as sputum and nasal discharge. Therefore, disinfectants (and disinfection methods) produced and approved using the currently recommended process can be insufficient for disinfection of infectious mucus, and deviations can occur between the expected effects and the actual clinical effects (7–10, 17–20). A disinfectant effectiveness assessment test under conditions reproducing the physical properties of infectious mucus should be added to the current assessment standards for disinfectant effective-
ness. Next-generation disinfectants developed/approved under these new disinfectant effectiveness assessment standards will be sufficiently effective against infectious mucus and will contribute greatly to the advancement of contact infection prevention.

Since the decrease in the effectiveness of EBDs on infectious mucus is attributable to the physical properties of mucus as a hydrogel, it is expected that the difference in the effectiveness of EBDs in saline and mucus conditions will be drastically reduced if the mucus is dried completely and the gel-like characteristics are lost. In fact, IAV both in dried mucus and in dried saline was rapidly inactivated within 30 s after exposure to EBD in both in vitro and in situ inactivation tests. For infectious mucus that is completely dried on fingers, EBDs exert IAV-inactivating effects in a short time (within 30 s), as conventionally recognized. In contrast, the IAV-inactivating effects of EBDs are extremely reduced against undried gelled infectious mucus. In other words, the current AHR regimen using EBDs is ineffective against infectious mucus before the mucus dries and is insufficient as a contact infection prevention measure.

In the current ASTM/CEN disinfectant effectiveness assessment test or in previous clinical studies, the effectiveness of disinfectants is generally evaluated after a sample (infectious body fluid) is placed on the test subject’s fingers and is completely dried (17–20, 32, 33). Thus, the reduction of disinfectant effectiveness against pathogens in undried mucus has not been paid enough attention so far. In our study, the time required for mucus (sputum) samples from IAV-infected patients to completely dry was approximately 30 min in an indoor environment (temperature, 25°C; humidity, 40%). EBD cannot exert sufficient inactivating effects on infectious mucus if the mucus is not completely dry, because infectious mucus maintains a gel form. For 30 min after infectious mucus has adhered to the hand and fingers, IAV in infectious mucus cannot be inactivated by AHR using EBD and remains transmittable; this increases the risk of spreading IAV infections.

Since the WHO announced the “Five moments for hand hygiene” recommendation in 2009, medical institutions around the world have been aiming to comply with this hand hygiene requirement (11, 34). However, our study revealed that “AHR immediately after treatment for IAV infected patients” cannot sufficiently inactivate IAV in infectious mucus, and infectious IAV can remain on the hand and fingers, since the infectious mucus is not dry. If sufficient time elapses before treating the next patient, “AHR before touching the next patient” completely inactivates IAV in infectious mucus adhering to the hand and fingers, because infectious mucus is completely dried. If there is an insufficient time or no time gap before treating the next patient, IAV in infectious mucus cannot be inactivated by “AHR before touching the next patient” because infectious mucus does not have time to dry completely. In these cases, the risk of spreading IAV to the patient to be treated next will be higher than expected. In contrast, even if there is an insufficient time or no time gap before treating the next patient, “AHW before touching the next patient” can completely inactivate IAV in infectious mucus.

As described above, situations where the effectiveness of EBD in infectious mucus is reduced (i.e., the current AHR vulnerability is exposed) are limited. However, in a realistic medical setting, a sufficient time interval cannot be secured between treatments, and the next patient’s treatment is performed immediately after the current patient’s treatment in many cases. Furthermore, since there is no time margin in such cases, simple and quick AHR rather than AHW is preferred and practiced for contact infection prevention (35, 36). However, situations where the current AHR regimen is preferred and practiced are exactly the situations where AHR has minimal efficacy.

The limitations of AHR must be overcome in the future. Since nonenveloped viruses (e.g., norovirus and adenovirus) are not easily inactivated by liquid disinfectants such as EBDs, prevention of contact infection with nonenveloped viruses is difficult (37–40). Although enveloped viruses such as IAV are usually inactivated relatively easily by EBDs, those present in undried infectious mucus are not effectively inactivated. Therefore, prevention of contact infection with enveloped viruses in undried infectious mucus should be performed in the same way as with nonenveloped virus. Moreover, “Com-
bination of means for drying mucus in a short time” and “Increase frequency of conventional AHW that washes out mucus physically instead of AHR” may also contribute to more effective contact infection prevention.

There were three limitations to this study. First, regarding the AHW regimens in this study, handwashing was practiced using running water only, without using plain or antiseptic soap. These AHW regimens were expected to have a lower pathogen inactivation effect compared to that of AHW regimens using plain or antiseptic soap. However, IAV on the fingers was completely inactivated within 30 s under all AHW conditions, showing a good IAV inactivation effect of AHW in this study. Therefore, this limitation did not affect the results and conclusions of this study. Second, the additional fluid simulation was performed with the mucus (sample no. 10) viscosity reduced to 16.7 or 12.5% of the measured value (Fig. 6; Fig. S4A). In the initial simulation of mucus conditions using the measured mucus viscosity, the time required for regions containing <31% ethanol to disappear exceeded 120 s. Times exceeding 120 s are not realistic, because the calculation time and costs are dramatically increased in the additional simulation reproducing the reaction conditions of the ethanol concentration measurement and the inactivation tests more faithfully. Therefore, the additional fluid simulation was performed with the mucus viscosity reduced. The result of the initial simulation under the same low-viscosity conditions (12.5 and 16.7% of the measured value) was as with the additional simulation (Fig. S4D); the results of actual measurement of ethanol concentrations in low-viscosity mucus (Fig. S4C) were generally compatible with the results of the additional simulation (Fig. S4A). The validity of the additional fluid simulation was confirmed, and it was demonstrated that the physical properties of mucus greatly affect the increase of ethanol concentration in mucus. Third, to estimate the time required for saline or mucus to completely dry up, the time required for samples to completely dry up on a glass plate was measured in an indoor environment. In the future, it will be necessary to establish a method for measuring the complete drying time of infectious mucus on human skin. Depending on the results of the future study, the complete drying time may vary slightly from a minimum of “30 min,” as shown in this study.

In this study, we showed that the disinfection effectiveness of EBDs against IAV decreases drastically in mucus; we further proposed a possible mechanism for this phenomenon. Additionally, we revealed the limitation of AHR, the main means of current hand hygiene, with reference to undried infectious mucus. These findings will greatly contribute not only to the development of a more effective method of preventing IAV outbreaks but also to the advancement of current hand hygiene and contact infection prevention strategies.

**MATERIALS AND METHODS**

**Viruses and cells.** Madin-Darby canine kidney (MDCK) cells were purchased from the Riken Bio-Resource Center Cell Bank (Ibaragi, Japan) and cultured in minimal essential medium (MEM; Sigma, St. Louis, MO, USA) supplemented with 10% fetal bovine serum and standard antibiotics (6, 41). IAV (PR8; A/Puerto Rico/8/1934; H1N1) was cultured in MDCK cells and stored as a working stock at −80°C. Viral titers were measured by focus-forming assays in MDCK cells and are expressed as the number of focus-forming units (FFU)/ml (6, 21).

**Collection of sputum samples and preparation of mucus.** Figure 7 shows the overall workflow of this study. Mucus samples (sputum samples [≥2 g]) were obtained from 52 individuals who were diagnosed with acute upper respiratory tract infection at the Kyoto Prefectural University of Medicine Hospital and its affiliated hospitals between September 2016 and March 2018. Individuals <20 years old, with chronic respiratory illness, or who were taking expectorants were excluded. The 52 mucus samples were evaluated by quantitative reverse transcription-PCR (qRT-PCR) to distinguish between IAV-infected and IAV-uninfected samples. Nucleic acids were extracted from the mucus samples with a PureLink RNA minikit (Thermo Fisher, Waltham, MA, USA), and cDNA was prepared using a ReverTra Ace qPCR RT master mix (Toyobo, Osaka, Japan) (6, 21). IAV was detected and quantified by qRT-PCR with a Thunderbird SYBR qPCR mix (Toyobo). IAV-specific PCR was performed with an IAV matrix protein genespecific primer set (M30F, 5’-TTCTAACCGGAGTTCGAAACG-3’; M264R2, 5’-ACAAAGCGTCTACGCTGCAG-3’) designed by the National Institute of Infectious Diseases (Tokyo, Japan). Results of the qRT-PCR analysis showed that 19 of the 52 samples were positive for IAV, and these 19 samples were used in this study.

To completely inactivate infectious IAV derived from the individuals, the samples were irradiated with UV light (10 mJ/cm²). Viral titration with MDCK cells was performed to confirm that no infectious IAV was
present. Bubbles were removed from irradiated samples by centrifugation at low speed to avoid destroying the mucous structure.

**Rheological analysis.** The viscosity of the mucus samples was measured with a DHR-1 controlled-stress rheometer (TA Instruments, New Castle, DE, USA) (42). A cone plate geometry (20 mm, 2°) was used at 25°C. A solvent trap containing distilled water prevented sample dehydration during measurement (43). Mucus (400 mg) was loaded onto the rheometer and left for 5 min to enable relaxation to the original gel structure. Steady-flow viscosities were measured with the flow-sweep mode (steady-flow measurement). Steady-flow viscosity (in Pas) and shear stress (in Pa) were determined with the Rheology Advantage data-analysis software (TRIOS Software, TA Instruments) for a range of shear rates (0.01, 0.016, 0.025, 0.04, 0.063, 0.1, 0.16, 0.25, 0.4, 0.63, 1.0, 1.6, 2.5, 4.0, 6.3, 10, 16, 25, 40, 63, and 100 s⁻¹). Steady-flow viscosity was calculated as shear stress divided by shear rate.

**Analysis of other physical properties.** The contact angles of pure water, saline, and sputum samples on a glass surface were measured with a contact angle meter (Asumigiken, Tokyo, Japan), and surface tensions were measured with a surface tension meter (Asumigiken).

**Analysis of complete drying time of saline and mucus.** The time required for 5 μl of saline or mucus samples to completely dry and solidify on a glass plate was measured. In an indoor environment (temperature, 25°C; humidity, 40%), 5 μl of each sample was placed on a glass dish and weighed over time. The weight decreased gradually due to the drying of the sample, and the time when the weight ceased to decrease was defined as the “complete drying time.” An analytical balance (XFR-135; Shinko Denshi, Tokyo, Japan) was used to measure the weight of the samples.

**Measurement of diffusion coefficients by PFG-NMR.** Three representative mucus samples (no. 1, 10, and 19) were selected, and the ethanol diffusion coefficients in these samples and those in saline were measured by pulsed-field gradient nuclear magnetic resonance (PFG-NMR). Samples were prepared by mixing deuterium oxide at 99.0 atom% D (D₂O; Isotech Laboratories, Inc., Champaign, IL, USA) and 99.5% ethanol (Kanto Chemical, Tokyo, Japan) into the mucus samples. Here, D₂O minimized the signal intensity from the OH group in ¹H NMR measurement. ¹H NMR spectra of the mucus-alcohol-D₂O mixtures were acquired at 298 ± 1 K. All NMR measurements were conducted using a Dif-30 diffusion probe on a Bruker Avance 600 spectrometer (Hitachi, Tokyo, Japan) operating at a ¹H resonance frequency of 600.13 MHz. The chemical shifts were calibrated using the ¹H resonance of tetramethylsilane as an external reference. PFG-NMR self-diffusion measurements were carried out using the pulsed-gradient spin-echo sequence, starting from the minimum value of 0.05 ms. The maximum gradient strength was adjusted experimentally to 2.0 to 3.0 Tm⁻¹ to maximize the accuracy of fitting from signal attenuation. The diffusion time (Δ) was fixed to 20 ms, and the gradient-pulse duration (δ) was set to 1 ms. For all samples, 5-mm NMR glass tubes were used; the tubes were sealed to prevent evaporation of the solvent. In total, eight signal averages were acquired for each gradient increment (g) for a total of 16 increments. The recycle time was 5 s, resulting in a total acquisition time for an individual PFG-NMR data set of <12 min.

The area (Ψ) of the respective resonance peaks was measured as a function of the gradient strength (g), and the self-diffusion coefficient (D) was determined using equation 1:

\[
Ψ = \exp\left(-\gamma^2 B_0^2 \xi^2 \left(\Delta - \frac{\delta}{3}\right)\right)
\]
where $\gamma$ is the gyromagnetic ratio of the $^1$H nucleus.

After measurement of the self-diffusion coefficients of the water and ethanol molecules, the interdiffusion coefficient ($D$) of the water-ethanol system was calculated from the self-diffusion coefficients of water ($D_{\text{H2O}}$) and ethanol ($D_{\text{EtOH}}$). $D$ was determined using Darken’s equation, as follows (2, 44, 45):

$$D = N_{\text{H2O}} \times D_{\text{H2O}} + N_{\text{EtOH}} \times D_{\text{EtOH}}$$  \hspace{1cm} (2)

where $N$ is the mole fraction.

Measurement of changes in ethanol concentration with a modified reflectometer. Changes in ethanol concentration in saline or mucus were measured after addition of 80% (wt/wt) ethanol-based disinfectant (EBD) (see Fig. S5A in the supplemental material). Ethanol concentrations were measured with a digital ethanol densitometer (ATAGO, Tokyo, Japan), which was modified for this measurement. The digital ethanol densitometer is a refractometer that measures the ethanol concentration at the center of a sample placed on a prism in a hemispherical region with a diameter of ~1 mm; this enables measurement of changes in ethanol concentration over time in the region of the sample with the lowest ethanol concentration. For this manual procedure, 95 $\mu$L of EBD was added as slowly as possible to a 5-$\mu$L sample placed on a prism. The densitometer was then used for measurement of the ethanol concentration over time. A fitting curve was prepared using the density, viscosity, and volume fraction of each fluid.

In vitro inactivation tests for evaluation of EBD efficacy against IAV. Tests for inactivation of IAV were carried out according to the following protocols (Fig. S5B), with EBD containing 80% (wt/wt) ethanol; established guidelines were followed for these tests (EN14476:2013/FprA1:2015) (19, 38, 46–48).

IAV was mixed with saline or mucus prior to EBD exposure. Briefly, 95 $\mu$L of EBD or PBS was added to 5 $\mu$L of a mixture of IAV and mucus or saline (final viral titer, $1.0 \times 10^6$ FFU/ml) in 24-well plates and incubated at $25^\circ C$ for 15, 30, 60, 120, 240, or 300 s prior to neutralization by dilution with 900 lMEM; titration of IAV was then performed. The survival ratio was calculated as the ratio of the titer after incubation with disinfectant to that measured after incubation with PBS; this ratio indicated the proportion of IAV that was not inactivated by the disinfectant. A fitting curve was prepared using the survival ratio at each time point, and complete inactivation was defined as a survival ratio below 10$^{-5}$. In addition, the mixture of IAV and saline or mucus was dried completely by letting the mixture stand for 40 min before EBD exposure, and the same inactivation test described above was carried out. For each measurement, three independent experiments were performed, and the results are expressed as the mean ± standard deviation (SD).

Clinical research (in situ inactivation tests for evaluation of EBD efficacy against IAV). Clinical research was performed with 10 test subjects who provided informed consent. Three representative mucus samples were selected (no. 1, 10, and 19), and the effectiveness of EBD against IAV in mucus or saline was examined using in situ inactivation tests conducted under established guidelines (finger pad protocol, ASTM E1838; hand wash protocol, EN14476) (32, 33, 47).

First, clinical research concerning the efficacy evaluation of AHR was performed (Fig. S5C). IAV was mixed with saline or mucus (final viral titer, $1.0 \times 10^6$ FFU/ml) and applied in 5-$\mu$L aliquots to washed and disinfected fingertips of test subjects in a marked area. A tube containing 95 $\mu$L of EBD was placed on the contaminated area and incubated for 30, 60, 120, or 240 s prior to neutralization and elution with 500 $\mu$L MEM; titration of IAV was then performed. The mixture of IAV and saline or mucus on fingertips was completely dried by standing for 40 min before exposure to EBD, and the same efficacy evaluation described above was carried out.

Next, clinical research concerning the efficacy evaluation of AHW was performed (Fig. S5D). IAV was mixed with saline or mucus (final viral titer, $1.0 \times 10^6$ FFU/ml) and applied in 5-$\mu$L aliquots to washed and disinfected fingertips of test subjects in a marked area. The contaminated fingers were hand washed with running water for 30, 60, 120, or 240 s prior to neutralization and elution with 500 $\mu$L MEM; IAV was then titrated. The mixture of IAV and saline or mucus on fingertips was completely dried by standing for 40 min after hand washing, and the same efficacy evaluation described above was carried out.

OpenFOAM simulation of changes in ethanol concentrations. OpenFOAM is an open-source software for continuum physics simulations and computational fluid dynamics. The InterMixingFoam solver of OpenFOAM 2.2.2 was used for this analysis. InterMixingFoam solved the incompressible Navier-Stokes equation and solved the conservation law of the volume fraction of each fluid (gas and two types of liquid). The volume fractions ($\alpha_1$, $\alpha_2$, and $\alpha_3$) satisfied equation 3:

$$\alpha_1 + \alpha_2 + \alpha_3 = 1$$  \hspace{1cm} (3)

In this analysis, the volume fraction, $\alpha_1$, was air, $\alpha_2$ was an 80% ethanol aqueous solution, and $\alpha_3$ was saline or mucus. The density ($\rho$) and viscosity ($\mu$) of the whole fluid could be obtained from equation 4 and equation 5 using the density, viscosity, and volume fraction of each fluid.

$$\rho = \rho_1 \alpha_1 + \rho_2 \alpha_2 + \rho_3 \alpha_3$$  \hspace{1cm} (4)

$$\mu = \mu_1 \alpha_1 + \mu_2 \alpha_2 + \mu_3 \alpha_3$$  \hspace{1cm} (5)

Additionally, the ethanol concentration ($x$) could be obtained from equation 6:

$$x = \left( \frac{80 \cdot \rho \alpha_2}{(\rho_1 \alpha_1 + \rho_2 \alpha_2 + \rho_3 \alpha_3)} \right)$$  \hspace{1cm} (6)
The entire fluid domain was analyzed using the Navier-Stokes equations, which include the law of conservation of mass (equation 7) and the law of conservation of momentum (equation 8).

\[
\frac{\partial \rho}{\partial t} + \nabla \cdot (\rho \mathbf{U}) = 0 \tag{7}
\]

\[
\frac{\partial \rho \mathbf{U}_i}{\partial t} + \nabla \cdot (\rho \mathbf{U}_i \mathbf{U}_j) = -\frac{\partial \rho}{\partial x_i} + \frac{\partial P}{\partial x_i} + \frac{\partial}{\partial x_j} (\mu \frac{\partial \mathbf{U}_i}{\partial x_j} + \rho g_i + (f_{12})_i + (f_{13})_i) \tag{8}
\]

where \( g \) is the gravitational acceleration and \( f_{12} \) and \( f_{13} \) are the surface tensions.

The surface tension \( (f_{12}) \) between the gas \( \alpha_1 \) and the liquid \( \alpha_2 \), and the surface tension \( (f_{13}) \) between the gas \( \alpha_1 \) and the liquid \( \alpha_3 \) can be obtained by the following equations, respectively (equation 9 and equation 10):

\[
f_{12} = \sigma_{12}(\nabla \cdot \mathbf{n}_{12})\mathbf{n}_{12} \tag{9}
\]

\[
f_{13} = \sigma_{13}(\nabla \cdot \mathbf{n}_{13})\mathbf{n}_{13} \tag{10}
\]

where \( \mathbf{n}_{12} \) and \( \mathbf{n}_{13} \) are normal vectors of the interface between the \( \alpha_1 \) and \( \alpha_2 \), and \( \alpha_1 \) and \( \alpha_3 \), respectively, and \( \sigma_{12} \) and \( \sigma_{13} \) are the surface tension coefficients of the interface between \( \alpha_1 \) and \( \alpha_2 \) and gas \( \alpha_1 \) and \( \alpha_3 \), respectively.

Finally, \( \alpha_1 \) and \( \alpha_2 \) were obtained by equation 11 and equation 12:

\[
\frac{\alpha_2}{dt} + \mathbf{U}_i \frac{\partial \alpha_2}{\partial x_i} = 0 \tag{11}
\]

\[
\frac{\alpha_2}{dt} + \mathbf{U}_i \frac{\partial \alpha_2}{\partial x_i} + D \frac{\partial^2 \alpha_2}{\partial x_i^2} = 0 \tag{12}
\]

where \( D \) is an interdiffusion coefficient. \( \alpha_2 \) was obtained from equation 3.

In the OpenFOAM code, the value of \( D \) was set to zero in places where \( \alpha_2 \) and \( \alpha_3 \) did not exist.

First, the initial simulation reproducing a mixing of 20 \( \mu \)l of saline or mucus and 480 \( \mu \)l of EBD in a 96-well plate was conducted (Fig. 3A). Fluid simulation was carried out for a total of four conditions using the physical property values of saline or those of the three mucus samples (no. 1, 10, and 19).

Next, the conditions of the additional simulation were set to reproduce the reaction conditions of EBD and saline or mucus in the inactivation tests as much as possible. Briefly, cubic meshes with sides of 0.2 mm were used for the simulation, and 95 \( \mu \)l of 80% ethanol was added at a flow rate of 250 \( \mu \)l/s from a height of 6.0 mm above 5 \( \mu \)l of saline or mucus (Fig. 3S). The physical properties of the sample (no. 10) with a median viscosity among all 19 mucus samples were adopted as the physical properties of the mucus used in the simulation. In the initial simple simulation of mucus conditions using the measured viscosity of mucus, the time required for regions containing <31% ethanol to disappear exceeded 120 s. Times exceeding 120 s are not realistic because the calculation time and cost are dramatically increased. Therefore, fluid simulation was performed with the mucus (sample no. 10) viscosity reduced to 16.7 or 12.5% of the measured value.

The physical properties and ethanol diffusion coefficient of the saline and mucus used in all simulations are shown in Fig. S6 in the supplemental material.

**Ethical considerations.** Informed consent was obtained from all participants. The study protocol was reviewed and approved by the Institutional Review Board of the Kyoto Prefectural University of Medicine (ERB-C-716-2, UMIN000030152).

**Statistical analysis.** Data were analyzed using GraphPad Prism 7 software (GraphPad, La Jolla, CA, USA). Differences between the means of continuous variables were evaluated by Student’s \( t \) test. Pearson’s correlation coefficient was used to assess the correlation between viscosity and 10, 20, and 31% ethanol concentration achievement time or between complete inactivation time and 31% ethanol concentration achievement time. For clinical data, the Wilcoxon signed rank test was performed. In this clinical study, under the condition that the Wilcoxon signed-rank test was performed under a normal distribution with an expected difference between log reductions of 2 and a standard deviation of 1, the required number of subjects was calculated to be 10 by the Monte Carlo simulation. All reported \( P \) values are two sided; \( P \) values of <0.05 were considered significant.

**SUPPLEMENTAL MATERIAL**

Supplemental material for this article may be found at [https://doi.org/10.1128/msphere.asm.org/00474-19](https://doi.org/10.1128/msphere.asm.org/00474-19).

**FIG S1**, TIF file, 1 MB.

**FIG S2**, TIF file, 0.9 MB.

**FIG S3**, TIF file, 2.3 MB.

**FIG S4**, TIF file, 1 MB.

**FIG S5**, TIF file, 2.8 MB.

**FIG S6**, TIF file, 1.1 MB.

**TABLE S1**, DOCX file, 0.1 MB.

**MOVIE S1**, MPG file, 5.4 MB.

**MOVIE S2**, MPG file, 8.2 MB.
Situations of Reduced Hand Hygiene Effectiveness

ACKNOWLEDGMENTS

We thank Hideki Sato and Yoshiki Iwai of Nissan Arc, Ltd., for assistance in measuring the ethanol diffusion coefficient by PFG-NMR and Tomoya Ioshimata and Kenta Ooi of Wave Front Co., Ltd., for assistance in the fluid simulation using CFD software. We thank all members of the Department of Infectious Diseases, Kyoto Prefectural University of Medicine, for support with the study.

This research was supported by AMED (grant no. JP18fk0108077) and JSPS KAKENHI (grant no. JP18K16183). This research was also supported by grants from the Mochida Memorial Foundation for Medical and Pharmaceutical Research, the Uehara Memorial Foundation, the Ichiro Kanehara Foundation, and the Daito Securities Health Foundation.

Study conception and design were performed by R.H. Data acquisition was performed by R.H., Y.N., T.D., R.B., K.I., O.D., N.Y., H.K., and Y.I. Data analysis and interpretation were performed by R.H., Y.N., T.D., R.B., K.I., O.D., N.Y., and H.K. The manuscript was drafted by R.H. Critical revision of the manuscript for intellectual content was performed by R.H., Y.I., and T.N. Statistical analysis was performed by R.H. Funding was secured by R.H. Administrative, technical, and material support was provided by R.H., T.N., and Y.I. Study supervision was performed by R.H. and T.N.

The authors declare no competing financial interests.

REFERENCES

1. Brankston G, Gitterman L, Hirji Z, Lemieux C, Gardam M. 2007. Transmission of influenza A in human beings. Lancet Infect Dis 7:257–265. https://doi.org/10.1016/S1473-3099(07)70029-4.

2. Breeze J, Hayden FG. 2013. Epidemic influenza—responding to the expected but unpredictable. N Engl J Med 368:589–592. https://doi.org/10.1056/NEJMmp1300375.

3. Breeding JV, Kiley B, Johnson-Frey E, Kim J, Dayan AD. 2004. Role of hospital-acquired infections in patients in the ICU. Crit Care Med 32:2468–2472. https://doi.org/10.1093/ccrcc/32.12.2468.

4. Brinkmann V, Jungers P, Schlosser O, Tziridis A, Kaser-Koch C, Pfisterer M, et al. 2001. Th2 cytokines inhibit nitrogenation of human alveolar macrophages. J Immunol 167:4110–4119. https://doi.org/10.4049/jimmunol.167.8.4110.

5. Brke PI, Stiarnakis NI. 2008. Inactivation of influenza A viruses in the environment and modes of transmissions: a critical review. J Infect 57:361–373. https://doi.org/10.1016/j.jinf.2008.08.013.

6. Hirose R, Daidoji T, Naito Y, Watanabe Y, Arai Y, Oda T, Konishi H, Yamawaki M, Itoh Y, Nakaya T. 2016. Long-term detection of seasonal influenza RNA in faeces and intestine. Clin Microbiol Infect 22:813.e1–813.e7. https://doi.org/10.1016/j.cmi.2016.06.015.

7. WHO. 2009. WHO guidelines on hand hygiene in health care. World Health Organization, Geneva, Switzerland.

8. Burke JP. 2003. Infection control—a problem for patient safety. N Engl J Med 348:651–652. https://doi.org/10.1056/NEJMhp020557.

9. Boyce JM, Pittet D. 2002. Guideline for hand hygiene in health-care settings. Recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/ SHEA/APIC/IDSA Hand Hygiene Task Force. Society for Healthcare Epidemiology of America/Association for Professionals in Infection Control/Infectious Diseases Society of America, MMWR Recomm Rep 51:1–45; quiz CE1–4.

10. Boyce JM, Pittet D. 2002. Guideline for hand hygiene in health-care settings. Recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Am J Infect Control 30(Suppl 5):S1–S46. https://doi.org/10.1016/S0196-6553(01)80001-1.

11. Longtin Y, Sax H, Algeranzi B, Schneider F, Pittet D. 2011. Videos in clinical medicine. Hand hygiene. N Engl J Med 364:e24. https://doi.org/10.1056/NEJMc1100399.

12. Kampe G, Kramer A. 2004. Epidemiologic background of hand hygiene and evaluation of the most important agents for scrubs and rubs. Clin Microbiol Rev 17:863–893; table of contents. https://doi.org/10.1128/CMR.17.4.863-893.2004.

13. Smith CR. 1947. Alcohol as a disinfectant against the tubercle bacillus. Public Health Rep 62:1285–1295. https://doi.org/10.2307/4586265.

14. Froebisch M, Jr, Sommermeyer L. 1953. A study of the effect of alcohols on tubercle bacilli and other bacteria in sputum. Am Rev Tuberc 68: 419–424.

15. Ulrich JA. 1981. Antimicrobial efficacy in the presence of organic matter, p 149–157. In Maibach HI, Aly R (ed), Skin microbiology: relevance to clinical infection. Springer, New York, NY.

16. Schaffer FL, Soergel ME, Straube DC. 1976. Survival of airborne influenza virus: effects of propagating host, relative humidity, and composition of spray fluids. Arch Virol 51:263–273. https://doi.org/10.1007/bf01317930.

17. CEN. 1997. CEN (European Committee for Standardization), EN 1500. Chemical disinfectants and antiseptics—hygienic handrub: test method and requirements (phase 2, step 2). CEN, Brussels, Belgium.

18. ASTM. 2003. Standard guide for assessment of antimicrobial activity using a time-kill procedure. ASTM E2315-03: USA, 2003. ASTM, West Conshohocken, PA.

19. CEN. 2015. Chemical disinfectants and antiseptics. Quantitative suspension test for the evaluation of virucidal activity in the medical area. Test method and requirements (phase 2/step 1). EN14476:2013/FprA1:2015. CEN, Brussels, Belgium.

20. CEN. 2002. Chemical disinfectants and antiseptics—virucidal quantitative suspension test for chemical disinfectants and antiseptics used in human medicine. Test method and requirements (phase 2/step 1). prEN 14476. CEN, Brussels, Belgium.

21. Hirose R, Nakaya T, Naito Y, Daidoji T, Watanabe Y, Yasuda H, Konishi H, Itoh Y. 2017. Mechanism of human influenza virus RNA persistence and virion survival in feces: mucus protects virions from acid and digestive juices. J Infect Dis 216:105–109. https://doi.org/10.1093/infdis/jix224.

22. Hirose R, Nakaya T, Naito Y, Daidoji T, Watanabe Y, Yasuda H, Konishi H, Itoh Y. 2017. Viscosity is an important factor of resistance to alcohol-based disinfectants by pathogens present in mucus. Sci Rep 7:13186. https://doi.org/10.1038/s41598-017-13732-2.

23. Yu FP, McFeters GA. 1994. Physiological responses of bacteria in biofilms to disinfection. Appl Environ Microbiol 60:2462–2466.

24. Huang CT, Yu FP, McFeters GA, Stewart PS. 1995. Nonuniform spatial patterns of respiratory activity within biofilms during disinfection. Appl Environ Microbiol 61:2252–2256.

25. Balcazar JL, Subirats J, Borrego CM. 2015. The role of biofilms as environmental reservoirs of antibiotic resistance. Front Microbiol 6:1216. https://doi.org/10.3389/fmicb.2015.01216.

26. Cogan NG. 2008. Two-fluid model of biofilm disinfection. Bull Math Biol 70:800–819. https://doi.org/10.1007/s11538-007-9280-3.
27. Stewart PS. 2003. Diffusion in biofilms. J Bacteriol 185:1485–1491. https://doi.org/10.1128/jb.185.5.1485-1491.2003.

28. Peulen TO, Wilkinson KJ. 2011. Diffusion of nanoparticles in a biofilm. Environ Sci Technol 45:3367–3373. https://doi.org/10.1021/es103450g.

29. Herrling MP, Weisbrodt J, Kirkland CM, Williamson NH, Lackner S, Codd SL, Seymour JD, Guthausen G, Horn H. 2017. NMR investigation of water diffusion in different biofilm structures. Biotechnol Bioeng 114:2857–2867. https://doi.org/10.1002/bit.26392.

30. Flemming HC, Wingender J, Szewzyk U, Steinberg P, Rice SA, Kjelleberg S. 2016. Biofilms: an emergent form of bacterial life. Nat Rev Microbiol 14:563–575. https://doi.org/10.1038/nrmicro.2016.94.

31. Lieleg O, Ribbeck K. 2011. Biological hydrogels as selective diffusion barriers. Trends Cell Biol 21:543–551. https://doi.org/10.1016/j.tcb.2011.06.002.

32. Sattar SA, Ansari SA. 2002. The fingerpad protocol to assess hygienic hand antiseptics against viruses. J Virol Methods 103:171–181. https://doi.org/10.1016/S0166-0934(02)00025-3.

33. Tuladhar E, Hazeleger WC, Koopmans M, Zwietering MH, Duizer E, Beumer RR. 2015. Reducing viral contamination from finger pads: hand-washing is more effective than alcohol-based hand disinfectants. J Hosp Infect 90:226–234. https://doi.org/10.1016/j.jhin.2015.02.019.

34. Salmon S, Pittet D, Sax H, McLaws ML. 2015. The ‘My five moments for hand hygiene’ concept for the overcrowded setting in resource-limited healthcare systems. J Hosp Infect 91:95–99. https://doi.org/10.1016/j.jhin.2015.04.011.

35. De Carvalho M, Lopes JM, Pellitteri M. 1989. Frequency and duration of handwashing in a neonatal intensive care unit. Pediatr Infect Dis J 8:179–180.

36. Tvedt C, Bukholm G. 2005. Alcohol-based hand disinfection: a more robust hand-hygiene method in an intensive care unit. J Hosp Infect 59:229–234. https://doi.org/10.1016/j.jhin.2004.10.003.

37. Howie R, Alfa MJ, Coombs K. 2008. Survival of enveloped and non-enveloped viruses on surfaces compared with other micro-organisms and impact of suboptimal disinfectant exposure. J Hosp Infect 69:368–376. https://doi.org/10.1016/j.jhin.2008.04.024.

38. Gehrk C, Steinmann J, Gorony-Bermes P 2004. Inactivation of feline calicivirus, a surrogate of norovirus (formerly Norwalk-like viruses), by different types of alcohol in vitro and in vivo. J Hosp Infect 56:49–55. https://doi.org/10.1016/j.jhin.2003.08.019.

39. Malik VS, Maherchandani S, Goyal SM. 2006. Comparative efficacy of ethanol and isopropanol against feline calicivirus, a norovirus surrogate. Am J Infect Control 34:31–35. https://doi.org/10.1016/j.ajic.2005.05.012.

40. Lages SL, Ramakrishnan MA, Goyal SM. 2008. In-vivo efficacy of hand sanitisers against feline calicivirus: a surrogate for norovirus. J Hosp Infect 68:159–163. https://doi.org/10.1016/j.jhin.2007.11.018.

41. Hirose R, Nakaya T, Daidoji T. 2016. Additional comments: long term detection of seasonal influenza RNA in faeces and intestine. Clin Microbiol Infect https://doi.org/10.1016/j.cmi.2016.09.020.

42. Broughton-Head VJ, Shur J, Carroll MP, Smith JR, Shute JK. 2007. Unfractionated heparin reduces the elasticity of sputum from patients with cystic fibrosis. Am J Physiol Lung Cell Mol Physiol 293:L1240–L1249. https://doi.org/10.1152/ajplung.00206.2007.

43. Hirose R, Nakaya T, Naito Y, Daidoji T, Doi O, Yoshida N, Yasuda H, Konishi H, Itoh Y. 2019. Identification of the critical viscoelastic factor in the performance of submucosal injection materials. Mater Sci Eng C Mater Biol Appl 94:909–919. https://doi.org/10.1016/j.msec.2018.10.051.

44. Eggers M, Eickmann M, Zorn J. 2015. Povidone-iodine hand wash and hand rub products demonstrated excellent in vitro virucidal efficacy against Ebola virus and modified vaccinia virus Ankara, the new European test virus for enveloped viruses. BMC Infect Dis 15:375. https://doi.org/10.1186/s12879-015-1111-9.

45. Eggers M, Eickmann M, Zorn J. 2015. Rapid and effective virucidal activity of povidone-iodine products against Middle East respiratory syndrome coronavirus (MERS-CoV) and modified vaccinia virus Ankara (MVA). Infect Dis Ther 4:491–501. https://doi.org/10.1007/s40121-015-0091-9.